Optina Diagnostics is revolutionizing medical diagnostics with our Retinal Deep Phenotyping platform that brings clarity and accessibility to early-stage diagnosis of diseases of the eye, and so much more. Optina aims to improve the lives of older adults by making diagnosis and precision medicine a reality. We are addressing major challenges faced by healthcare systems that support aging populations. The Optina-4C hyperspectral camera for imaging the retina (back of the eye) is FDA-cleared and licensed by Health Canada. It brings a new dimension to medical imaging - the power of the spectral (color) dimension - and reveals unprecedented information about cellular and molecular changes. Optina's Retinal Deep Phenotyping platform combines data-rich images from the Optina-4C camera with Artificial intelligence-driven algorithms to deliver automated, accessible, and equitable diagnostic information about eye diseases like Age-related Macular Degeneration, as well as systemic diseases like Alzheimer's and cardiac stenosis. Optina has been granted Breakthrough Device Designation by the FDA for our Alzheimer's test which enables a dramatic improvement in the differential diagnosis of dementia.
Looking for a particular Optina Diagnostics employee's phone or email?
The Optina Diagnostics annual revenue was $4 million in 2026.
Dave Anderson is the CEO and President of Optina Diagnostics.
13 people are employed at Optina Diagnostics.
Optina Diagnostics is based in Montréal, Québec.
The NAICS codes for Optina Diagnostics are [54, 62, 62151, 6215, 621, 541].
The SIC codes for Optina Diagnostics are [73, 807, 737, 80].